NASDAQ$ALT
Altimmune Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Altimmune reported financial results for the first quarter of 2021 and provided a corporate update.
Altimmune reported a net loss of $14.9 million, or $0.38 net loss per share, for the three months ended March 31, 2021. The company's cash, cash equivalents and short-term investments totaled $226.5 million at March 31, 2021.
- AdCOVID and ALT-801 are advancing in the clinic, with data readouts from both clinical trials expected in June.
- The company plans to transition into a comprehensive global Phase 2 clinical development program if the data from the AdCOVID Phase 1 trial are positive.
- ALT-801 is progressing through its first-in-human clinical trial in Australia, with 6-week data anticipated to be available later this quarter.
- Altimmune had cash, cash equivalents and short-term investments totaling $226.5 million at March 31, 2021.
Headline financials
Revenue & EPS history
Altimmune · Revenue · Quarterly
$838K
Forward guidance
Altimmune anticipates key milestones for its clinical assets, including data readouts from the AdCOVID Phase 1 clinical trial in June 2021 and the potential start of the AdCOVID Phase 2 clinical program in Q2 2021. The company also expects the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) phases of the ALT-801 study, with 6-week data expected in June 2021 and 12-week data in Q3 2021.
Tailwinds
- Data readout from AdCOVID Phase 1 clinical trial expected in June 2021.
- Potential start of AdCOVID Phase 2 clinical program in Q2 2021.
- Completion of single ascending dose (SAD) and multiple ascending dose (MAD) phases of the ALT-801 study.
- 6-week data from ALT-801 study expected in June 2021.
- 12-week data from ALT-801 study expected in Q3 2021.
Headwinds
- Potential impacts due to the COVID-19 pandemic such as delays in regulatory review.
- Manufacturing and supply chain interruptions.
- Access to clinical sites, enrollment challenges.
- Adverse effects on healthcare systems.
- Disruption of the global economy.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
+2.4%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+5.6%
Avg return
30 days after
60%
21 / 35 earnings
Positive
+35.0%
Q2 2022
Best reaction
-25.1%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -8.8% | -15.3% | |
| Q4 2025 | -17.6% | -9.6% | -21.8% | |
| Q3 2025 | +5.1% | +14.1% | +39.7% | |
| Q1 2025 | -4.2% | -7.2% | +19.0% | |
| Q4 2024 | +8.1% | +0.3% | -10.4% | |
| Q3 2024 | +29.5% | +3.5% | +16.9% | |
| Q2 2024 | +12.2% | +14.7% | +12.7% | |
| Q1 2024 | +0.8% | +9.2% | -9.8% | |
| Q4 2023 | +17.7% | +18.3% | -16.1% | |
| Q3 2023 | +1.1% | -6.4% | +146.4% | |
| Q2 2023 | +2.0% | -4.7% | -16.9% | |
| Q1 2023 | +2.2% | -6.6% | -19.7% | |
| Q4 2022 | +1.9% | -2.0% | -64.3% | |
| Q3 2022 | +10.3% | +12.7% | +4.2% | |
| Q2 2022 | +35.0% | +37.3% | +55.4% | |
| Q1 2022 | +31.0% | +34.3% | +117.0% | |
| Q4 2021 | +2.2% | +12.1% | -18.7% | |
| Q3 2021 | -0.5% | +1.3% | -12.3% | |
| Q2 2021 | +6.6% | +14.9% | +56.8% | |
| Q1 2021 | +5.2% | +4.7% | +23.0% | |
| Q4 2020 | -18.6% | -19.5% | -29.3% | |
| Q3 2020 | -25.1% | -18.6% | -1.1% | |
| Q2 2020 | -13.5% | -5.5% | -54.3% | |
| Q1 2020 | +21.4% | +21.6% | +103.8% | |
| Q4 2019 | -7.1% | -6.5% | -2.8% | |
| Q3 2019 | -8.0% | -10.9% | -1.7% | |
| Q2 2019 | -6.5% | -6.5% | -0.9% | |
| Q1 2019 | +2.7% | -4.7% | -3.5% | |
| Q4 2018 | +3.4% | +6.6% | -0.7% | |
| Q3 2018 | -6.8% | -9.1% | -31.5% | |
| Q2 2018 | +4.9% | +0.3% | -21.0% | |
| Q1 2018 | +10.8% | -1.9% | +1.7% | |
| Q4 2017 | -8.3% | -5.9% | -36.0% | |
| Q3 2017 | -1.0% | -7.1% | -25.1% | |
| Q2 2017 | -10.3% | -12.0% | +11.6% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro